Skip to main content

HLN 6-K

Haleon plc (HLN)

6-K 2025-06-03 For: 2025-06-03
View Original
Added on April 05, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form<br>20-F ☒ Form<br>40-F ☐

EXHIBIT INDEX

Exhibit Number Description
99.1 03 June<br>2025- “Director/PDMR Shareholding”

99.1

Haleon plc: Director/PDMR Shareholding

3 June 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

On 2 June 2025, Ed Petter, Chief Corporate Affairs Officer, received the vesting of the first tranche of an award of Haleon Ordinary Shares under the Haleon Share Value Plan. The award was granted as part of his remuneration arrangements upon joining Haleon, to compensate for forfeited incentives from his previous employment.

The award is subject to malus and clawback provisions.

Further details are set out in the below notification, made in accordance with the requirements of The UK Market Abuse Regulations.

1 Details of the person discharging managerial responsibilities /<br>person closely associated
a) Name Ed<br>Petter
2 Reason for the notification
a) Position/status Chief<br>Corporate Affairs Officer
b) Initial notification /Amendment Initial<br>Notification
3 Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction<br>monitor
a) Name Haleon<br>plc
b) LEI 549300PSB3WWEODCUP19
4 Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted
a) Description of the financial instrument, type of<br>instrument<br><br><br><br><br><br>Identification<br>code Ordinary Shares of 0.01 each<br><br> <br><br><br>GB00BMX86B70
b) Nature of the transaction Acquisition of Ordinary Shares in respect of the first vesting of<br>the Haleon plc Share Value Plan (Buyout award).
c) Price(s) and volume(s) Price(s)
Nil
d) Aggregated information<br><br><br><br><br><br>- Aggregated volume<br><br><br><br><br><br>- Price N/A
e) Date of the transaction 2 June 2025
f) Place of the transaction Outside a trading venue
4 Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted
a) Description of the financial instrument, type of<br>instrument<br><br><br><br><br><br>Identification<br>code Ordinary Shares of 0.01 each<br><br> <br><br><br>GB00BMX86B70
b) Nature of the transaction Automatic disposal of Ordinary Shares resulting from Haleon plc<br>Share Value Plan (Buyout award) vesting to cover tax<br>liabilities.
c) Price(s) and volume(s) Price(s)
4.134623
d) Aggregated information<br><br><br><br><br><br>- Aggregated volume<br><br><br><br><br><br>- Price N/A
e) Date of the transaction 2 June 2025
f) Place of the transaction London Stock Exchange (XLON)

All values are in British Pounds.

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HALEON PLC<br><br><br>(Registrant)
Date: June 03,<br>2025 By: /s/<br>Amanda Mellor
Name: Amanda<br>Mellor
Title: Company<br>Secretary